| Impact of lipophilic efficiency on compound quality A Tarcsay, K Nyíri, GM Keserű Journal of medicinal chemistry 55 (3), 1252-1260, 2012 | 181 | 2012 |
| Highly potent dUTPase inhibition by a bacterial repressor protein reveals a novel mechanism for gene expression control JE Szabo, V Németh, V Papp-Kádár, K Nyíri, I Leveles, AA Bendes, ... Nucleic acids research 42 (19), 11912-11920, 2014 | 59 | 2014 |
| Cross-species inhibition of dUTPase via the Staphylococcal Stl protein perturbs dNTP pool and colony formation in Mycobacterium R Hirmondó, JE Szabó, K Nyíri, S Tarjányi, P Dobrotka, J Tóth, ... DNA repair 30, 21-27, 2015 | 34 | 2015 |
| Structure and enzymatic mechanism of a moonlighting dUTPase I Leveles, V Németh, JE Szabó, V Harmat, K Nyíri, ÁÁ Bendes, ... Acta Crystallographica Section D: Biological Crystallography 69 (12), 2298-2308, 2013 | 34 | 2013 |
| Evidence-based structural model of the staphylococcal repressor protein: separation of functions into different domains K Nyíri, B Kőhegyi, A Micsonai, J Kardos, BG Vertessy PLoS One 10 (9), e0139086, 2015 | 23 | 2015 |
| Structural model of human dUTPase in complex with a novel proteinaceous inhibitor K Nyíri, HDT Mertens, B Tihanyi, GN Nagy, B Kőhegyi, J Matejka, ... Scientific Reports 8 (1), 4326, 2018 | 22 | 2018 |
| Assessment of tractable cysteines for covalent targeting by screening covalent fragments L Petri, P Ábrányi‐Balogh, I Tímea, G Pálfy, A Perczel, D Knez, M Hrast, ... ChemBioChem 22 (4), 743-753, 2021 | 18 | 2021 |
| Structure-based inhibitor design of mutant RAS proteins—a paradigm shift K Nyíri, G Koppány, BG Vértessy Cancer and Metastasis Reviews 39, 1091-1105, 2020 | 18 | 2020 |
| On the stability of six-membered-ring carbenes and silylenes K Nyiri, T Veszprémi Organometallics 28 (20), 5909-5914, 2009 | 17 | 2009 |
| The mechanism and energetics of insertion reactions of silylenes K Nyíri, T Szilvási, T Veszprémi Dalton Transactions 39 (39), 9347-9352, 2010 | 16 | 2010 |
| Perturbation of genome integrity to fight pathogenic microorganisms K Nyíri, BG Vértessy Biochimica et Biophysica Acta (BBA)-General Subjects 1861 (1), 3593-3612, 2017 | 13 | 2017 |
| In Vitro Analysis of Predicted DNA-Binding Sites for the Stl Repressor of the Staphylococcus aureus SaPIBov1 Pathogenicity Island V Papp-Kádár, JE Szabó, K Nyíri, BG Vertessy PLoS One 11 (7), e0158793, 2016 | 13 | 2016 |
| Exploring the role of the phage-specific insert of bacteriophage Φ11 dUTPase K Nyíri, V Papp-Kádár, JE Szabó, V Németh, BG Vértessy Structural Chemistry 26, 1425-1432, 2015 | 13 | 2015 |
| Unique Insertion Mechanisms of Bis-dehydro-β-diketiminato Silylene T Szilvási, K Nyíri, T Veszprémi Organometallics 30 (20), 5344-5351, 2011 | 12 | 2011 |
| HDX and native mass spectrometry reveals the different structural basis for interaction of the staphylococcal pathogenicity island repressor Stl with dimeric and trimeric phage … K Nyíri, MJ Harris, J Matejka, O Ozohanics, K Vékey, AJ Borysik, ... Biomolecules 9 (9), 488, 2019 | 9 | 2019 |
| Exploiting a phage-bacterium interaction system as a molecular switch to decipher macromolecular interactions in the living cell ÉV Surányi, R Hírmondó, K Nyíri, S Tarjányi, B Kőhegyi, J Tóth, ... Viruses 10 (4), 168, 2018 | 9 | 2018 |
| Mechanism-Based Redesign of GAP to Activate Oncogenic Ras D Berta, S Gehrke, K Nyíri, BG Vértessy, E Rosta Journal of the American Chemical Society 145 (37), 20302-20310, 2023 | 3 | 2023 |
| Covalent fragment mapping of KRasG12C revealed novel chemotypes with in vivo potency Z Orgován, N Péczka, L Petri, P Ábrányi-Balogh, I Ranđelović, S Tóth, ... European Journal of Medicinal Chemistry 250, 115212, 2023 | 2 | 2023 |
| Correction to impact of lipophilic efficiency on compound quality A Tarcsay, K Nyíri, GM Keserű Journal of Medicinal Chemistry 56 (7), 3120-3120, 2013 | 2 | 2013 |
| Redesigned GAP to activate oncogenic GAP D Berta, S Gehrke, K Nyíri, BG Vértessy, E Rosta | 1 | 2023 |
Beata G. VertessyProfessor, EI RCNS HUN-REN, BME HungaryVerified email at kutatok.org
